Health In Tech, Inc. (HIT) intrinsic value & 10-year financials
Health In Tech, Inc. (HIT) has a Graham intrinsic value of $0.66 per share. At $0.65 on Oct 17, 2026, the stock trades 2% below that value. Over the last 4 fiscal years revenue grew 39.7% a year to $37.6M, with an average return on invested capital of 44.5%.
- Graham intrinsic value
- $0.66
- Share price (Oct 17, 2026)
- $0.65
- Price vs Graham value
- 2% below
- Market cap
- $37.6M
- Revenue (FY2025)
- $37.6M
- Revenue growth (4-yr CAGR)
- 39.7%
- ROIC (10-yr avg)
- 44.5%
- Free cash flow (FY2025)
- —
HIT 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $37.6M | $1.3M | $0.02 | — | — | 17.1% |
| FY2024 | $19.6M | $670.5K | $0.01 | — | — | 14.4% |
| FY2023 | $19.2M | $4.0M | — | — | — | 101.9% |
| FY2022 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Health In Tech, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Health In Tech, Inc. has earned high returns on invested capital, averaging 44.5% ROIC over the available history. High ROIC is consistent with a durable franchise, but it is not by itself proof of an economic moat.
Health In Tech, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Health In Tech, Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $0.66 per share.